Published in Viruses on November 09, 2009
Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer (2013) 1.27
The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. PLoS One (2012) 0.88
The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer (2014) 0.78
WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues. J Cell Commun Signal (2015) 0.76
Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer (2014) 0.75
Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells. Int J Mol Sci (2017) 0.75
Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation. World J Hepatol (2015) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Hepatocellular carcinoma. Lancet (2003) 22.54
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Liver fibrosis. J Clin Invest (2005) 17.27
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Liver regeneration. J Cell Physiol (2007) 6.69
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Tumor heterogeneity. Cancer Res (1984) 6.17
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med (2003) 6.06
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26
Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A (1998) 4.99
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature (1990) 4.10
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
The interplay between MYC and HIF in cancer. Nat Rev Cancer (2008) 3.97
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev (2004) 3.91
Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol (2004) 3.41
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
The COP9 signalosome. Annu Rev Cell Dev Biol (2003) 3.25
Ras enhances Myc protein stability. Mol Cell (1999) 2.91
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Cancer stem cells--old concepts, new insights. Cell Death Differ (2008) 2.56
Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology (2006) 2.33
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Genetics of hepatocellular carcinoma. Semin Cancer Biol (2000) 2.30
Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A (1991) 2.27
Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol (2000) 2.18
The role of c-myc in cell growth. Curr Opin Genet Dev (1993) 2.17
beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer (2001) 2.17
Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology (2001) 2.12
Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion (2002) 2.09
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer (2003) 2.09
A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology (2006) 1.99
Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest (1994) 1.93
The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell (2005) 1.90
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol (2001) 1.88
Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell (2007) 1.87
Making myc. Curr Top Microbiol Immunol (2006) 1.87
Liver cancer stem cells. J Clin Oncol (2008) 1.82
Comparative and integrative functional genomics of HCC. Oncogene (2006) 1.75
Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology (2003) 1.74
Beta-catenin is temporally regulated during normal liver development. Gastroenterology (2004) 1.69
Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol (1999) 1.66
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut (2005) 1.66
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer (2008) 1.59
Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell (1988) 1.58
NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene (2008) 1.58
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res (2003) 1.55
Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell (2006) 1.54
Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res (2002) 1.53
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res (1994) 1.47
Twisted epithelial-mesenchymal transition blocks senescence. Nat Cell Biol (2008) 1.42
Telomere reduction in human liver tissues with age and chronic inflammation. Exp Cell Res (2000) 1.42
Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene (1998) 1.36
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33
Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology (2002) 1.30
Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A (1997) 1.29
The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle (2007) 1.28
Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett (2005) 1.26
Cellular senescence: its role in tumor suppression and aging. Cancer Sci (2009) 1.23
Beta-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo. Mol Cell Biol (2007) 1.21
Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology (1999) 1.19
Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer (2001) 1.16
Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology (2001) 1.16
Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol (2002) 1.16
Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology (2007) 1.15
Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci (2006) 1.13
CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinog (2001) 1.09
Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology (2007) 1.08
Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol (1992) 1.06
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology (2005) 1.04
Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion. Oncogene (1994) 1.02
Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology (2009) 1.01
Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol (1989) 0.99
ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. Biochem Biophys Res Commun (2005) 0.97
Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther (2006) 0.96
Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology (2006) 0.94
Susceptibility of chimeric mice with livers repopulated by serially subcultured human hepatocytes to hepatitis B virus. Hepatology (2008) 0.91
Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma. Hepatogastroenterology (1999) 0.89
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 9.35
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A (2002) 4.52
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol (2006) 1.72
Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: epidemiologic and biomolecular study. J Gastroenterol Hepatol (2006) 1.70
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys (2006) 1.51
Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis (2007) 1.47
Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol (2004) 1.24
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology (2003) 1.19
Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology (2002) 1.10
Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol (2006) 1.09
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant (2005) 1.08
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol (2012) 1.05
Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One (2012) 1.05
Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther (2008) 1.01
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 1.00
Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. J Infect Dis (2004) 0.99
Sarcoidosis and hepatitis C: clinical description of 11 cases. Eur J Gastroenterol Hepatol (2010) 0.98
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis (2004) 0.95
Genotype determination in Moroccan hepatitis B chronic carriers. Infect Genet Evol (2008) 0.95
Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol (2005) 0.95
Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol (2010) 0.94
Smoking and non-Hodgkin's lymphoma: a case-control study in the Rhône-Alpes region of France. Cancer Causes Control (2003) 0.94
Microsporidiosis and transplantation: a retrospective study of 23 cases. J Eukaryot Microbiol (2003) 0.92
Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers. J Infect (2011) 0.92
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob Agents Chemother (2013) 0.91
Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine (2003) 0.89
The incidence of herpes zoster is less likely than other opportunistic infections to be reduced by highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 0.87
Identification of novel recombinants of hepatitis B virus genotypes F and G in human immunodeficiency virus-positive patients from Argentina and Brazil. J Gen Virol (2012) 0.87
A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus. J Gen Virol (2005) 0.87
Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Hepatol Res (2008) 0.87
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol (2009) 0.85
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int (2006) 0.85
Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol (2005) 0.84
Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice. Oncogene (2003) 0.84
The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2010) 0.82
Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape. J Infect Dis (2012) 0.82
DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J Gen Virol (2008) 0.81
Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). J Hepatol (2005) 0.81
Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C. J Hepatol (2004) 0.80
Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver Int (2014) 0.80
Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study. Gastroenterol Clin Biol (2007) 0.80
Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther (2010) 0.80
The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. J Med Virol (2004) 0.80
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int (2008) 0.80
Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes. J Hepatol (2005) 0.80
Liver histological alterations in patients with chronic hepatitis C and normal ALT levels in the city of Salvador, Northeast-Brazil. Braz J Infect Dis (2005) 0.79
Interferon-based treatment of chronic hepatitis C. Biochimie (2007) 0.79
Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo. J Acquir Immune Defic Syndr (2007) 0.79
Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation (2005) 0.79
Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model. Hepatology (2010) 0.79
Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle? J Hepatol (2007) 0.78
First presentation for care of HIV-infected patients with low CD4 cell count in Lyon, France: risk factors and consequences for survival. AIDS Care (2012) 0.78
Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir Ther (2009) 0.78
Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. J Gen Virol (2006) 0.77
High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients. Eur J Gastroenterol Hepatol (2010) 0.77
Efficient hepatitis C antigen immunohistological staining in sections of normal, cirrhotic and tumoral liver using a new monoclonal antibody directed against serum-derived HCV E2 glycoproteins. Cancer Lett (2006) 0.77
Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months? J Hepatol (2002) 0.75
Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. Ther Drug Monit (2016) 0.75
[Glucagonoma revealed by necrolytic migratory erythema]. Gastroenterol Clin Biol (2003) 0.75
Congenital malformations of the suprahepatic inferior vena cava: an easily overlooked etiology of chronic liver disease with tumor-like nodules. Dig Dis Sci (2006) 0.75
Hypertensive crisis, hepatitis B virus and polyarteritis nodosa in a child. Pediatr Nephrol (2006) 0.75
[Study of the antiviral mechanism of action of ribavirin in the bovine viral diarrhea virus model]. Gastroenterol Clin Biol (2002) 0.75
[Phytosoya(R)-induced cytolytic hepatitis]. Gastroenterol Clin Biol (2002) 0.75
Clinical, histologic and serologic evaluation of patients with acute non-A-E hepatitis in north-eastern Brazil: is it an infectious disease? Int J Infect Dis (2003) 0.75
[Lyme's disease presenting as increased gamma-GT activity]. Gastroenterol Clin Biol (2002) 0.75
Occult B infection in the Brazilian northeastern region: a preliminary report. Braz J Infect Dis (2008) 0.75